Abstract #3952

Androgen receptor signaling in castration resistant prostate cancer tumor alters real-time lactate flux and lactate levels in vivo

Niki Zacharias^1,2, Jaehyuk Lee³, Sumankalai Ramachandran⁴, Sriram Shanmugavelandy³, James McHenry ³, Sankar Maity ⁴, Mark Titus ⁴, and Pratip Bhattacharya³

¹Urology, University of Texas MD Anderson Cancer Center, Houston, TX, United States, ²Bioengineering, Rice University, Houston, TX, United States, ³Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁴Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Non-invasive imaging of castration resistant prostate cancer (CRPC) subtypes remains a challenge in the clinic. CRPC can be subdivided grossly into two phenotypes 1) a morphologically small cell, chemosensitive, and androgen receptor (AR) negative subtype and 2) AR-dependent CRPC characterized by dysregulation of AR signaling. Employing hyperpolarized pyruvate conversion to lactate in vivo as well as lactate measurements ex vivo, we determined the difference in glycolysis between patient derived xenograft (PDX) animal models of these two CRPC subtypes. We have found increased pyruvate to lactate conversion (P <0.04) and higher lactate levels in AR-dependent compared to AR negative PDX models.

This abstract and the presentation materials are available to members only; a login is required.

Join Here